MARKETS / COMPANIES / ECONOMYRSS edition ↗
Dividend Monitor
Company News

Cipla misses second-quarter profit view on muted US sales

SENSEX 73,368.60 -238.15 NIFTY 22,710.05 -43.15 CRUDEOIL 9,742.00 + 19.00 GOLD 142,407.00 -666.00 SILVER 191,955.00 -3,838.00 SENSEX 73,368.60 -238.15 NIFTY 22,710.05 -43.15 NIFTY 22,710.05 -43.15 CRUDEOIL 9,742.00 + 19…

Cipla misses second-quarter profit view on muted US sales
SENSEX 73,368.60

 -238.15

NIFTY 22,710.05

 -43.15

CRUDEOIL 9,742.00

+ 19.00

GOLD 142,407.00

 -666.00

SILVER 191,955.00

 -3,838.00

SENSEX 73,368.60

 -238.15

NIFTY 22,710.05

 -43.15

NIFTY 22,710.05

 -43.15

CRUDEOIL 9,742.00

+ 19.00

CRUDEOIL 9,742.00

+ 19.00

GOLD 142,407.00

 -666.00

'; } document.getElementById("lgdv").innerHTML = htmlElements; } function numberformat(i) { return Number(parseFloat(i).toFixed(2)).toLocaleString('en', { minimumFractionDigits: 2 }) } async function gatherResponse(response) { const { headers } = response; const contentType = headers.get('content-type') || ''; if (contentType.includes('application/json')) { return await response.json() } return response.text(); } function getWidth() { if (Math.max(document.body.scrollWidth,document.documentElement.scrollWidth,document.body.offsetWidth,document.documentElement.offsetWidth,document.documentElement.clientWidth) > 991) { document.getElementById("mob").style.display = "none"; document.getElementById("lgdv").style.display = "block"; } else { document.getElementById("mob").style.display = "block"; document.getElementById("lgdv").style.display = "none"; } } getWidth(); THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS.THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS.

Cipla’s consolidated ​net ‌profit fell to ₹878 crore ($92.2 million) ‌in the ​quarter ended September 30, ⁠from ₹1,351 crore a ‌year ago

By PTI

Updated - October 27, 2026 at 02:00 PM. | Oct 27

Muted sales ‌of Cipla’s generic Revlimid ‌and stiff ‌competition ⁠weighed on ⁠its US business | Photo Credit: bl-online Administrator

Cipla, the country's third-largest ​drugmaker by ‌revenue, missed second-quarter ​profit estimates ⁠on Tuesday, as muted sales ‌of generic Revlimid ‌and stiff ‌competition ⁠weighed on ⁠its US business.

The company's consolidated ​net ‌profit fell to ₹878 crore ($92.2 million) ‌in the ​quarter ended September 30, ⁠from ₹1,351 crore a ‌year ago.

Analysts, on average, had expected profit ‌to fall to ​₹942 crore, according to ⁠data compiled ⁠by LSEG.

Published on October 27, 2026

Companies to follow
  • Cipla Ltd
THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS. THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS. THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS. THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS.Sign into Unlock benefits!
  • Access 10 free stories per month
  • Get notified by email for early preview to new features, discounts & offers
Source: The Hindu BusinessLine — Companies ↗

Figures reflect the source report and its stated period. This article is for information and is not investment advice.